Feb 27, 2024 / 09:30PM GMT
Operator
Good day, ladies and gentlemen, and welcome to ACADIA Pharmaceuticals Fourth Quarter and Full Year 2023 Financial Results Conference Call. My name is Abigail, and I will be your coordinator for today.(Operator Instructions)
I would now like to turn the presentation over to Al Kildani, Senior Vice President of Investor Relations and Corporate Communications at ACADIA. Please proceed.
Albert S. Kildani - ACADIA Pharmaceuticals Inc. - SVP of IR & Corporate Communications
Good afternoon, and thank you for joining us on today's call to discuss ACADIA's Fourth Quarter and Full Year 2023 Earnings Results. Joining me on the call today from ACADIA are Steve Davis, our Chief Executive Officer, who will provide some opening remarks, followed by Brendan Teehan, our Chief Operating Officer and Head of Commercial, who will discuss our strong commercial franchises, DAYBUE and NUPLAZID. Doug Williamson, our Head of Research and Development, will provide an update on our pipeline programs. And Mark Schneyer, our Chief Financial Officer, will review the financial
Q4 2023 ACADIA Pharmaceuticals Inc Earnings Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot